insmed - Search News

News

US FDA approves Insmed's drug

Insmed CEO on what’s next for company after FDA greenlights lung disease drug

Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for for the stock.

Reuters on MSN · 1d

US FDA approves Insmed's drug as first treatment for a chronic lung disease

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition. Shares of the New Jersey-based drugmaker rose 6% in afternoon trade.

UPI on MSN · 10h

First drug to treat bronchiectasis lung condition approved by FDA

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the brand name Brinsupri.

12h

PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

Fierce Pharma1d

Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor

With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit ...

Asianet Newsable on MSN6h

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have ...

VytlOne Announces New Partnership with Insmed

Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri™. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the ...

Insmed (INSM) Receives a Buy from Leerink Partners

Schwartz covers the Healthcare sector, focusing on stocks such as uniQure, KalVista Pharmaceuticals, and Insmed. According to TipRanks, Schwartz has an average return of 15.6% and a 47.59% success ...

5don MSN

Insmed outlines $405M–$425M ARIKAYCE revenue target as brensocatib nears launch and pipeline advances

Q2 2025 Management View William H. Lewis, President, CEO & Chairman, highlighted, "Insmed is now three for three, all three ...

Don't Overlook Insmed (INSM) International Revenue Trends While Assessing the Stock

Explore Insmed's (INSM) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Jefferies Remains a Buy on Insmed (INSM)

In a report released today, Kelly Shi from Jefferies maintained a Buy rating on Insmed, with a price target of $129.00. The company’s shares closed today at $109.30. Elevate You ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results